Last $45.16 USD
Change Today +0.17 / 0.38%
Volume 3.1M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:04 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for glaxosmithkline plc-spon adr (GSK)

Year over year, GlaxoSmithKline plc has seen revenues remain relatively flat ($39.8B USD to $39.9B USD), though the company was able to grow net income from $6.8B USD to $8.2B USD. A reduction in the percentage of sales devoted to income tax expense from 7.27% to 3.84% was a key component in the bottom line growth in the face of flat revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Reclassified
GBP
Dec 31
2011
Restated
GBP
Dec 31
2012
Restated
GBP
Dec 31
2013
GBP
4 Year
Trend
Revenues42,770.641,256.639,816.539,927.9
TOTAL REVENUES42,770.641,256.639,816.539,927.9
Cost of Goods Sold11,599.511,558.811,470.012,086.1
GROSS PROFIT31,171.029,697.828,346.527,841.8
Selling General & Admin Expenses, Total12,173.512,875.511,949.011,933.9
R&D Expenses5,781.76,055.85,399.05,352.3
Other Operating Expenses-473.0-501.6-510.7-573.9
OTHER OPERATING EXPENSES, TOTAL17,482.118,429.716,837.416,712.3
OPERATING INCOME13,688.911,268.111,509.111,129.5
Interest Expense-1,155.4-1,122.3-1,123.8-1,095.2
Interest and Investment Income155.2128.0110.088.9
NET INTEREST EXPENSE-1,000.3-994.2-1,013.8-1,006.3
Income (Loss) on Equity Investments122.022.643.764.8
Other Non-Operating Income (Expenses)-72.3-81.3-90.4-57.2
EBT, EXCLUDING UNUSUAL ITEMS12,738.410,215.110,448.610,130.7
Merger & Restructuring Charges-2,030.7---839.1-778.8
Impairment of Goodwill----186.8--
Gain (Loss) on Sale of Investments-60.3786.4381.1376.6
Gain (Loss) on Sale of Assets342.0485.1995.82,128.6
Other Unusual Items, Total-6,233.6---1,230.8-1,843.9
Legal Settlements-6,027.2---656.8-379.6
Other Unusual Items----284.7-378.1
EBT, INCLUDING UNUSUAL ITEMS4,755.811,486.59,942.410,013.2
Income Tax Expense1,964.43,344.32,895.41,535.1
Minority Interest in Earnings-329.9-296.8-269.7-289.2
Earnings from Continuing Operations2,791.48,142.37,047.18,478.2
NET INCOME2,461.57,845.56,777.48,189.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS2,461.57,845.56,777.48,189.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS2,461.57,845.56,777.48,189.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $45.16 USD +0.17

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $166.13 USD +2.19
AbbVie Inc $63.12 USD +1.27
Amgen Inc $156.37 USD +1.73
Bristol-Myers Squibb Co $61.14 USD -0.19
Sanofi €82.19 EUR -0.07
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 16.2x
Price/Sales 2.8x
Price/Book 13.2x
Price/Cash Flow 16.1x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.